ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Vitamin D2 (ergocalciferol): Drug information

Vitamin D2 (ergocalciferol): Drug information
(For additional information see "Vitamin D2 (ergocalciferol): Patient drug information" and see "Vitamin D2 (ergocalciferol): Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Calcidol [OTC];
  • Calciferol [OTC] [DSC];
  • Drisdol;
  • Ergocal [DSC]
Brand Names: Canada
  • D-Forte;
  • SANDOZ D-Forte
Pharmacologic Category
  • Vitamin D Analog
Dosing: Adult

Note: 1 mcg = 40 units

Osteoporosis prevention

Osteoporosis prevention (off-label use): Oral: Adults ≥50 years of age: 800 to 1,000 units/day (20 to 25 mcg/day) is recommended, through dietary sources and/or supplementation if needed (NOF [Cosman 2014]).

Vitamin D insufficiency/deficiency

Vitamin D insufficiency/deficiency (off-label use):

Note: The optimal serum 25-hydroxyvitamin D (25[OH]D) level has not been established; generally, deficiency is defined as 25(OH)D levels <12 ng/mL (<30 nmol/L), and insufficiency is defined as 25(OH)D levels 12 to <20 ng/mL (30 to <50 nmol/L) (Giustina 2019). Therefore, some experts suggest a target range of 20 to 40 ng/mL (50 to 100 nmol/L) for most patients (Dawson-Hughes 2022). Individualize dose based on patient-specific factors (eg, presence of malabsorption, liver disease, kidney disease) and target 25(OH)D level and ensure adequate calcium intake during therapy (Dawson-Hughes 2022; NOF [Cosman 2014]). The following recommendations are based primarily on expert opinion and clinical experience:

Prevention:

Oral: 600 to 1,000 units (15 to 25 mcg) once daily (IOM 2011; NOF [Cosman 2014]).

Treatment:

Initial dosing:

High-dose therapy: May be preferred in patients with a serum 25(OH)D level <12 ng/mL (<30 nmol/L) or who are symptomatic (eg, bone fracture/pain, muscle weakness), or in patients with concomitant hypocalcemia (Dawson-Hughes 2022; Goltzman 2022; NOF [Cosman 2014]).

Oral: 50,000 units (1,250 mcg) once weekly (or equivalent dose administered once daily) for 6 to 12 weeks, then recheck 25(OH)D level; may repeat high-dose therapy if needed to achieve target 25(OH)D level (Dawson-Hughes 2022; Goltzman 2022; NOF [Cosman 2014]).

Low-dose therapy: May be preferred in patients with a serum 25(OH)D level 12 to <20 ng/mL (30 to <50 nmol/L) without symptoms or concomitant hypocalcemia (Dawson-Hughes 2022).

Oral: 800 to 1,000 units (20 to 25 mcg) once daily for ~3 to 4 months; may adjust dose if needed every 3 to 4 months based on 25(OH)D level. Some experts suggest modest dose increases (eg, to 2,000 units [50 mcg] once daily) if serum 25(OH)D levels have substantially increased but remain below target or switching to high-dose therapy if serum 25(OH)D levels remain substantially below target (Dawson-Hughes 2022).

Maintenance dosing: Oral: Once target 25(OH)D level is achieved, continue at a maintenance dose of 600 to 2,000 units (15 to 50 mcg) once daily (Dawson-Hughes 2022; NOF [Cosman 2014]).

Special populations (eg, obesity, patients on medications known to affect vitamin D metabolism, malabsorption, gastrectomy): Higher doses or longer durations may be necessary for adequate replacement. In patients with malabsorption when target 25(OH)D levels cannot be maintained with ergocalciferol, consider switching to hydroxylated vitamin D metabolites (eg, calcitriol) (Brandi 2013; Dawson-Hughes 2022).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

In patients with chronic kidney disease (CKD) G3a to G5D, Kidney Disease Improving Global Outcomes guidelines recommend correcting vitamin D deficiency and insufficiency with treatment strategies recommended for patients without kidney impairment. In patients with CKD G4 to G5 with severe and progressive hyperparathyroidism despite correction of modifiable factors (eg, hyperphosphatemia, vitamin D deficiency), calcitriol or vitamin D analogs are suggested (KDIGO 2017).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Vitamin D2 (ergocalciferol): Pediatric drug information")

Note: 1 mcg = 40 USP units.

Hypoparathyroidism

Hypoparathyroidism: Infants, Children, and Adolescents: Oral: 50,000 to 200,000 units (1,250 to 5,000 mcg) daily with calcium supplements.

Vitamin D deficiency, prevention

Vitamin D deficiency, prevention (eg, Rickets prevention) (AAP [Golden 2014]; Abrams 2020; Munns 2016):

Breastfed infants (fully or partially): Oral: 400 units (10 mcg) daily beginning in the first few days of life; continue supplementation unless infant is transitioned to full formula intake.

Children and Adolescents without adequate intake: Oral: 600 units (15 mcg) daily. Note: Children with increased risk of vitamin D deficiency (chronic fat malabsorption, maintained on chronic antiseizure medications) may require higher doses. Use laboratory testing [25(OH)D, PTH, bone mineral status] to evaluate.

Vitamin D deficiency, treatment

Vitamin D deficiency (severe, symptomatic), treatment: Note: Treatment should also include calcium; some patients with chronic fat malabsorption, obesity, or who are maintained on chronic antiseizure medications, glucocorticoids, HIV medications, or antifungals may require higher doses of ergocalciferol (AAP [Golden 2014]); monitor vitamin D status closely:

Infants: Oral: 2,000 units (50 mcg) daily for 6 weeks to achieve a serum 25(OH)D level >20 ng/mL; followed by a maintenance dose of 400 to 1,000 units (10 to 25 mcg) daily. Note: For patients at high risk of fractures a serum 25(OH)D level >30 ng/mL has been suggested (AAP [Golden 2014]).

Children and Adolescents: Oral: 2,000 units (50 mcg) daily for 6 to 8 weeks to achieve a serum 25(OH)D level >20 ng/mL; followed by a maintenance dose of 600 to 1,000 units (15 to 25 mcg) daily. Note: For patients at high risk of fractures a serum 25(OH)D level >30 ng/mL has been suggested (AAP [Golden 2014]).

Vitamin D insufficiency or deficiency associated with CKD; serum 25 hydroxyvitamin D level <30 ng/mL

Vitamin D insufficiency or deficiency associated with CKD (stages 2 to 5, 5D); serum 25 hydroxyvitamin D (25[OH]D) level <30 ng/mL: (K/DOQI Guidelines 2009):

Serum 25(OH)D level 16 to 30 ng/mL: Infants, Children, and Adolescents: Oral: 2,000 units (50 mcg) daily for 3 months or 50,000 units (1,250 mcg) every month for 3 months.

Serum 25(OH)D level 5 to 15 ng/mL: Infants, Children, and Adolescents: Oral: 4,000 units (100 mcg) daily for 12 weeks or 50,000 units (1,250 mcg) every other week for 12 weeks.

Serum 25(OH)D level <5 ng/mL: Infants, Children, and Adolescents: Oral: 8,000 units (200 mcg) daily for 4 weeks then 4,000 units (100 mcg) daily for 2 months for total therapy of 3 months or 50,000 units (1,250 mcg) weekly for 4 weeks followed by 50,000 units (1,250 mcg) 2 times monthly for a total therapy of 3 months.

Maintenance dose [once repletion accomplished; serum 25(OH)D level >30 ng/mL]: Infants, Children, and Adolescents: Oral: 200 to 1,000 units (5 to 25 mcg) daily.

Rickets

Rickets:

Nutritional rickets, treatment: Limited data available (Munns 2016): Administer in combination with calcium supplementation:

Daily therapy (preferred):

Infants: Oral: 2,000 units (50 mcg) daily for ≥3 months, followed by maintenance dose of 400 units (10 mcg) daily.

Children: Oral: 3,000 to 6,000 units (75 to 150 mcg) daily for ≥3 months, followed by maintenance dose of 600 units (15 mcg) daily.

Adolescents: Oral: 6,000 units (150 mcg) daily for ≥3 months, followed by maintenance dose of 600 units (15 mcg) daily.

Single-dose therapy: Note: While ergocalciferol can be used, cholecalciferol is the preferred supplement for single-dose therapy due to longer half-life

Infants ≥3 months: Oral: 50,000 units (1,250 mcg) once, or in divided doses over several days; after 3 months, initiate maintenance dose of 400 units (10 mcg) daily.

Children: Oral: 150,000 units (3,750 mcg) once, or in divided doses over several days; after 3 months, initiate maintenance dose of 600 units (15 mcg) daily.

Adolescents: Oral: 300,000 units (7,500 mcg) once, or in divided doses over several days; after 3 months, initiate maintenance dose of 600 units (15 mcg) daily.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling; however, ergocalciferol is not renally eliminated to a significant extent and dosage adjustment is not necessary.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Frequency not defined: Endocrine & metabolic: Hypervitaminosis D

Contraindications

Hypercalcemia; malabsorption syndrome; abnormal sensitivity to the toxic effects of vitamin D; hypervitaminosis D.

Note: Although the manufacturer's labeling lists use in malabsorption syndrome as contraindicated, when dosed appropriately, ergocalciferol may be used in these patients (AACE/ACE [Camacho 2020]; Dawson-Hughes 2022).

Warnings/Precautions

Concerns related to adverse effects:

• Vitamin D toxicity: May occur with excessive doses; symptoms may include nausea, vomiting, loss of appetite, constipation, dehydration, fatigue, irritability, confusion, weakness, and/or weight loss. Effects of vitamin D can last ≥2 months after therapy is discontinued.

Disease-related concerns:

• Hyperphosphatemia: Normal serum phosphorous concentrations must be maintained in patients treated for hyperphosphatemia to prevent metastatic calcification.

Dosage form specific issues:

• Propylene glycol: Oral solutions may contain propylene glycol; toxicities may occur if large doses of vitamin D are required. Alternate dosage forms/products should be used (Misra 2008).

• Tartrazine: Products may contain tartrazine, which may cause allergic reactions in certain individuals.

Warnings: Additional Pediatric Considerations

Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral:

Drisdol: 1250 mcg (50000 unit) [contains fd&c blue #1 (brilliant blue), fd&c yellow #5 (tartrazine), soybean oil]

Ergocal: 62.5 mcg (2500 unit) [DSC] [gluten free; contains fd&c blue #1 (brill blue) aluminum lake, gelatin (bovine), quinoline yellow (d&c yellow #10), soybean lecithin]

Generic: 1250 mcg (50000 unit)

Solution, Oral:

Calcidol: 200 mcg/mL (8000 unit/mL) (60 mL) [alcohol free, dye free, gluten free, lactose free, sugar free; contains propylene glycol]

Calciferol: 200 mcg/mL (8000 unit/mL) (60 mL [DSC]) [contains propylene glycol]

Generic: 200 mcg/mL (8000 unit/mL) (60 mL)

Tablet, Oral:

Generic: 10 mcg (400 unit), 50 mcg (2000 unit)

Generic Equivalent Available: US

Yes

Pricing: US

Capsules (Drisdol Oral)

1.25 MG(50000 UT) (per each): $3.49

Capsules (Ergocalciferol Oral)

1.25 MG(50000 UT) (per each): $0.72

Solution (Calcidol Oral)

200 mcg/mL (per mL): $1.66

Solution (Ergocalciferol Oral)

200 mcg/mL (per mL): $0.59 - $1.67

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Generic: 1250 mcg (50000 unit)

Administration: Pediatric

Oral: May be administered without regard to meals; for oral liquid, administer with an accurate measuring device; do not use a household teaspoon (overdosage may occur).

Use: Labeled Indications

Dietary supplement: For use as a vitamin D supplement.

Use: Off-Label: Adult

Osteoporosis, prevention; Vitamin D insufficiency/deficiency

Medication Safety Issues
Sound-alike/look-alike issues:

Calciferol may be confused with calcifediol, calcitriol

Drisdol may be confused with Drysol

Ergocalciferol may be confused with alfacalcidol, cholecalciferol

Administration issues:

Liquid vitamin D preparations have the potential for dosing errors when administered to infants. Droppers should be clearly marked to easily provide 400 units. For products intended for infants, the FDA recommends that accompanying droppers deliver no more than 400 units per dose.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations. Risk D: Consider therapy modification

Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs. Risk C: Monitor therapy

Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. Risk C: Monitor therapy

Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs. Risk C: Monitor therapy

Erdafitinib: Serum Phosphate Level-Altering Agents may diminish the therapeutic effect of Erdafitinib. Management: Avoid coadministration of serum phosphate level-altering agents with erdafitinib before initial dose increase period based on serum phosphate levels (Days 14 to 21). Risk D: Consider therapy modification

Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations. Risk D: Consider therapy modification

Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs. Risk X: Avoid combination

Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs. Risk X: Avoid combination

Orlistat: May decrease the absorption of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or 2 hours after the administration of orlistat. Avoid concomitant administration due to the risk of impaired vitamin absorption. Risk D: Consider therapy modification

Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs. Risk C: Monitor therapy

Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs. Risk X: Avoid combination

Pregnancy Considerations

The ergocalciferol (vitamin D2) metabolite, 25(OH)D, crosses the placenta; maternal serum concentrations correlate with fetal concentrations at birth (Misra 2008; Wagner 2008).

Vitamin D deficiency in a pregnant woman may lead to a vitamin D deficiency in the neonate (Misra 2008; Wagner 2008). Serum 25(OH)D concentrations should be measured in pregnant women considered to be at increased risk of deficiency (ACOG 2011). The amount of vitamin D contained in prenatal vitamins may not be adequate to treat a deficiency during pregnancy; although larger doses may be needed, current guidelines recommend a total of 1000 to 2000 units/day until more safety data is available (ACOG 2011). In women not at risk for deficiency, doses larger than the RDA should be avoided during pregnancy (ACOG 2011).

Maternal vitamin D requirements are the same for breastfeeding and nonbreastfeeding females (IOM 2011). The maternal dose of vitamin D needed to provide the infant with an adequate amount of vitamin D is still under study (Wagner 2008)

Breastfeeding Considerations

The 25(OH)D metabolite can be detected in breast milk. The manufacturer recommends that caution be used if ergocalciferol is administered to nursing women. Hypercalcemia has been noted in a breastfeeding infant following maternal use of large amounts of vitamin D; calcium serum concentrations should be monitored in nursing infants exposed to large doses.

Small quantities of vitamin D are found in breast milk following normal maternal exposure via sunlight and diet. The amount in breast milk does not correlate with serum levels in the infant and the vitamin D content of human milk is not enough to meet the recommended intake for a nursing infant. Therefore, vitamin D supplementation is recommended in all infants who are partially or exclusively breast fed (Misra 2008; Wagner 2008).

Dietary Considerations

Vitamin D is found in egg yolks, fatty fish, fortified milk, fortified cereal, and infant formulas; it is also produced by exposure to sunlight (IOM 2011).

Dietary Reference Intake for Vitamin D (IOM 2011):

Infants 0 to 12 months: Adequate intake: 10 mcg/day (400 units/day)

1 to 70 years: RDA: 15 mcg/day (600 units/day)

>70 years: RDA: 20 mcg/day (800 units/day)

Pregnancy/Lactating: RDA: 15 mcg/day (600 units/day)

Monitoring Parameters

Signs/symptoms of vitamin D toxicity (eg, hypercalcemia, hypercalciuria, confusion, psychosis, tremor, calcification of soft tissue, nausea, weakness) (ASPEN [McKeever 2017])

Adults:

Serum 25(OH)D: For patients being treated for vitamin D deficiency with a baseline serum 25(OH)D level <20 ng/mL (50 nmol/L), measure ~3 to 4 months after initiation or dosage adjustment. In healthy patients initiating maintenance dosing, routine monitoring is not required (Dawson-Hughes 2022).

Additional monitoring of calcium, phosphorous, parathyroid hormone (PTH), and alkaline phosphatase may be required depending on severity of 25(OH)D deficiency and/or concomitant clinical condition (eg, chronic kidney disease, hypoparathyroidism) (Dawson-Hughes 2022; ES [Brandi 2016]; KDIGO 2017).

Infants, Children, and Adolescents:

Vitamin D deficiency: Serum calcium, phosphorus, and alkaline phosphatase (ALP) one month after starting therapy; serum calcium, phosphorous, magnesium, ALP, 25(OH)D, and PTH as well as x-ray (may also consider urine calcium/creatinine ratio) after 3 months; 25(OH)D yearly (Misra 2008).

Increased risk of vitamin D deficiency (eg, chronic fat malabsorption, chronic antiseizure medication use): Serum 25(OH)D, PTH, and bone mineral status (baseline); if vitamin D supplement is required, repeat 25(OH)D levels at 3-month intervals until normal. PTH and bone mineral status should be monitored every 6 months until normal (Wagner 2008).

CKD: Measure serum 25(OH)D levels after 3 months of treatment. Measure corrected total calcium and phosphorous after 1 month and then at least every 3 months (KDOQI 2009).

Reference Range

Vitamin D deficiency: There is no clear consensus on a reference range for total serum 25(OH)D concentrations or the validity of this level as it relates clinically to bone health. In addition, there is significant variability in the reporting of serum 25(OH)D levels as a result of different assay types in use. However, the following ranges have been suggested:

Adults:

<12 ng/mL (30 nmol/L): At risk for deficiency (IOM 2011).

12 to 20 ng/mL (30 to 50 nmol/L): Potentially at risk for inadequacy (IOM 2011).

≥20 ng/mL (50 nmol/L): Sufficient levels in practically all persons (IOM 2011).

>40 ng/mL (100 nmol/L): Increased risk of falls have been reported in elderly females with levels >40 ng/mL (Smith 2017) or ~48 ng/mL (120 nmol/mL) (Sanders 2010).

>50 ng/mL (125 nmol/L): There are insufficient data to determine the safe upper limit of serum 25(OH)D. Serum 25(OH)D levels above approximately 50 ng/mL (125 nmol/L) should be avoided (IOM 2011).

Osteoporosis patients: Recommended level to reach and maintain may vary by guideline/organization: ≥20 ng/mL (50 nmol/L) is considered adequate according to some experts (ES [Eastell 2019]); others suggest a goal of ~30 ng/mL (75 nmol/L) (NOF [Cosman 2014]).

Children (Misra 2008):

<15 ng/mL (37.5 nmol/L): At risk for deficiency.

15 to 20 ng/mL (37.5 to 50 nmol/L): Potentially at risk for inadequacy.

≥20 ng/mL (50 nmol/L): Sufficient levels in practically all children.

>100 ng/mL (250 nmol/L): Concern for risk of toxicity.

Mechanism of Action

Ergocalciferol (vitamin D2) is a provitamin. The active metabolite, 1,25-dihydroxyvitamin D (calcitriol), stimulates calcium and phosphate absorption from the small intestine, promotes secretion of calcium from bone to blood; promotes renal tubule phosphate resorption.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: 10 to 24 hours; Maximum effect: ~1 month following daily doses

Absorption: Absorbed in the small intestine; fat soluble; requires bile (IOM 2011)

Metabolism: Inactive until hydroxylated hepatically to 25-hydroxyvitamin D [25(OH)D; calcifediol] then renally to the active metabolite 1,25-dihydroxyvitamin D (calcitriol)

Half-life, circulating: 25(OH)D: 2 to 3 weeks; 1,25-dihydroxyvitamin D ~4 hours

Excretion: Feces (IOM 2011)

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: D forte;
  • (AU) Australia: Ostelin;
  • (BR) Brazil: Ergocalciferol d2 | Vitamina d2;
  • (CN) China: Vitamin D2;
  • (CZ) Czech Republic: Calciferol;
  • (EC) Ecuador: Vitamina d;
  • (EG) Egypt: Devarol | Ossofortin;
  • (GB) United Kingdom: Calciferol | Rx d2;
  • (GR) Greece: Ostelin;
  • (HK) Hong Kong: Calciferol | Mega-Cal;
  • (IE) Ireland: Drisdol | Vitamin D2;
  • (IT) Italy: Ostelin;
  • (LT) Lithuania: Calciferol | Vitamin d;
  • (LU) Luxembourg: Sterogyl;
  • (LV) Latvia: Calciferol | Vitamin d;
  • (MX) Mexico: Vd4 | Vitamina d2;
  • (NO) Norway: Afi-d2 forte;
  • (NZ) New Zealand: Calciferol;
  • (PL) Poland: Kalcyfediol | Vitamin d;
  • (PR) Puerto Rico: Drisdol | Vitamin d | Vitamin D2 | Vitamina d;
  • (QA) Qatar: Calciferol Biotika Forte;
  • (SK) Slovakia: Calciferol | Calciferol bbp;
  • (TH) Thailand: Calciferol | Vitamin D2;
  • (VE) Venezuela, Bolivarian Republic of: Vitamina d;
  • (ZA) South Africa: Calciferol
  1. Abrams SA, Committee on Nutrition. Calcium and vitamin D requirements of enterally fed preterm infants. Pediatrics. 2013;131(5):e1676-1683. [PubMed 23629620]
  2. Abrams SA. Vitamin D in preterm and full-term infants. Ann Nutr Metab. 2020;76(suppl 2):6-14. doi:10.1159/000508421 [PubMed 33232955]
  3. ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 495: Vitamin D: Screening and supplementation during pregnancy. Obstet Gynecol. 2011;118(1):197-198. doi:10.1097/AOG.0b013e318227f06b [PubMed 21691184]
  4. Agostoni C, Buonocore G, Carnielli VP, et al. Enteral nutrient supply for preterm infants: commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2010;50(1):85-91. doi:10.1097/MPG.0b013e3181adaee0 [PubMed 19881390]
  5. American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  6. Brandi ML, Bilezikian JP, Shoback D, et al. Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab. 2016;101(6):2273-2283. doi:10.1210/jc.2015-3907 [PubMed 26943719]
  7. Brandi ML, Minisola S. Calcidiol [25(OH)D3]: from diagnostic marker to therapeutical agent. Curr Med Res Opin. 2013;29(11):1565-1572. doi:10.1185/03007995.2013.838549 [PubMed 24020910]
  8. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract. 2020;26(suppl 1):S1-S46. doi:10.4158/GL-2020-0524SUPPL [PubMed 32427503]
  9. Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia [published correction appears in J Bone Miner Res. 2015;30(2):394]. J Bone Miner Res. 2011;26(7):1381-1388. doi:10.1002/jbmr.340 [PubMed 21538511]
  10. Cosman F, de Beur SJ, LeBoff MS, et al; National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359-2381. doi:10.1007/s00198-014-2794-2 [PubMed 25182228]
  11. Dawson-Hughes B. Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 20, 2022.
  12. Drisdol (ergocalciferol) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; July 2018.
  13. Drisdol capsule (ergocalciferol) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; May 2012.
  14. Drisdol solution (ergocalciferol) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; June 2008.
  15. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. doi:10.1210/jc.2019-00221 [PubMed 30907953]
  16. FDA consumer update. Infant overdose risk with liquid vitamin D. June 15, 2010. https://www.fda.gov/forconsumers/consumerupdates/ucm214343.htm. Accessed March 11, 2019.
  17. Folsom LJ, DiMeglio LA. Recommendations released on prevention, management of rickets. AAP News. http://www.aappublications.org/news/2017/02/10/Rickets021017. Published February 10, 2017. Accessed October 19, 2018.
  18. Giustina A, Adler RA, Binkley N, et al. Controversies in vitamin D: summary statement from an international conference. J Clin Endocrinol Metab. 2019;104(2):234-240. doi:10.1210/jc.2018-01414 [PubMed 30383226]
  19. Golden NH, Abrams SA; Committee on Nutrition. Optimizing bone health in children and adolescents. Pediatrics. 2014;134(4):e1229-e1243. doi:10.1542/peds.2014-2173 [PubMed 25266429]
  20. Goltzman D. Treatment of hypocalcemia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 9, 2022.
  21. Greer FR. Vitamin metabolism and requirements in the micropremie. Clin Perinatol. 2000;27(1):95-118, vi. [PubMed 10690566]
  22. Institute of Medicine (IOM). Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press; 2011.
  23. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Guideline 7. Prevention and treatment of vitamin D insufficiency and vitamin D deficiency in CKD patients. http://kidneyfoundation.cachefly.net/professionals/KDOQI/guidelines_bone/guide7.htm. Published 2003. Accessed October 31, 2018.
  24. KDOQI Work Group. KDOQI clinical practice guideline for nutrition in children with CKD: 2008 update. Executive summary. Am J Kidney Dis. 2009;53(3)(suppl 2):S11-S104. doi:10.1053/j.ajkd.2008.11.017 [PubMed 19231749]
  25. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, Part 4. Definition and Classification of Stages of Chronic Kidney Disease. Am J Kidney Dis. 2002;39(2)(suppl 1):46-75.
  26. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter. 2013;3:1-150.
  27. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59. https://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf. Accessed October 25, 2018.
  28. McKeever L. Vitamins and Trace Elements. In: Mueller CM, ed. A.S.P.E.N. Adult Nutrition Support Core Curriculum. 3rd edition. Silver Spring, MD: American Society for Parenteral and Enteral Nutrition; 2017:146. http://www.nutritioncare.org/
  29. Misra M, Pacaud D, Petryk A, et al. Vitamin D Deficiency in Children and Its Management: Review of Current Knowledge and Recommendations. Pediatrics. 2008;122(2):398-417. [PubMed 18676559]
  30. Munns CF, Shaw N, Kiely M, et al. Global consensus recommendations on prevention and management of nutritional rickets. J Clin Endocrinol Metab. 2016;101(2):394-415. doi:10.1210/jc.2015-2175 [PubMed 26745253]
  31. National Osteoporosis Foundation (NOF). Clinician’s guide to prevention and treatment of osteoporosis. Washington, DC, 2014. http://nof.org/hcp/resources/913
  32. Sanchez CP. Secondary Hyperparathyroidism in Children With Chronic Renal Failure: Pathogenesis and Treatment. Paediatr Drugs. 2003;5(11):763-776. [PubMed 14580225]
  33. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial [published correction appears in JAMA. 2010;303(23):2357]. JAMA. 2010;303(18):1815-1822. doi:10.1001/jama.2010.594 [PubMed 20460620]
  34. Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259. [PubMed 19188870]
  35. Smith LM, Gallagher JC, Suiter C. Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: A randomized clinical trial. J Steroid Biochem Mol Biol. 2017;173:317-322. doi:10.1016/j.jsbmb.2017.03.015 [PubMed 28323044]
  36. Stechschulte SA, Kirsner RS, Federman DG. Vitamin D: Bone and Beyond, Rationale and Recommendations for Supplementation. Am J Med. 2009;122(9):793-802. [PubMed 19699370]
  37. Wagner CL, Greer FR; American Academy of Pediatrics Section on Breastfeeding; American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics. 2008;122(5):1142-1152. doi:10.1542/peds.2008-1862 [PubMed 18977996]
Topic 10150 Version 387.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟